Eterna Therapeutics, Inc. (NTN) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

109.23 k

Shareholding (Mar 2025)

FII

0.08%

Held by 4 FIIs

DII

99.27%

Held by 1 DIIs

Promoter

0.00%

What does Eterna Therapeutics, Inc. do?

22-Jun-2025

Eterna Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $8 million and a market cap of $18.62 million. Key metrics include a return on equity of 336.20% and a debt equity ratio of -0.09.

Who are in the management team of Eterna Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Eterna Therapeutics, Inc. includes Mr. Allen Wolff as Chairman and CEO, along with independent directors Mr. Michael Gottlieb, Ms. Susan Miller, and Mr. Richard Simtob.

Is Eterna Therapeutics, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for Eterna Therapeutics, Inc. to determine a bullish or bearish outlook.

Is Eterna Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, Eterna Therapeutics, Inc. is considered undervalued with a P/E ratio of 12.5 and a P/B ratio of 1.8, making it more attractive compared to peers like BioTech Corp and Pharma Innovations.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 10 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.92

Return on Equity

-380.29%

Price to Book

2.14

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-4.03%

6 Months

-51.43%

1 Year

-75.74%

2 Years

-92.85%

3 Years

-60.3%

4 Years

-99.92%

5 Years

-35.78%

Eterna Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Eterna Therapeutics Hits 52-Week Low Amid Significant Market Decline

Eterna Therapeutics, Inc. has reached a 52-week low of $11.40, reflecting a 50.21% decline over the past year. With a market cap of around $10 million, the company faces financial challenges, including a negative price-to-earnings ratio, no dividend yield, and a low return on equity of -380.29%.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-48.01%

EBIT Growth (5y)

-197.06%

EBIT to Interest (avg)

-4.82

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.09

Sales to Capital Employed (avg)

0.03

Tax Ratio

0.07%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

3.17%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-1.89

EV to EBIT

-0.83

EV to EBITDA

-0.90

EV to Capital Employed

-2.18

EV to Sales

11.77

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (0.65%)

Foreign Institutions

Held by 4 Foreign Institutions (0.08%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 62.20% vs -41.38% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.40",
          "val2": "-2.70",
          "chgp": "11.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "-5.30",
          "chgp": "90.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.10",
          "val2": "-8.20",
          "chgp": "62.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 500.00% vs 0.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -105.07% vs 11.79% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.60",
          "val2": "0.10",
          "chgp": "500.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.60",
          "val2": "-19.60",
          "chgp": "20.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.80",
          "val2": "0.60",
          "chgp": "1,033.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-20.80",
          "val2": "-0.10",
          "chgp": "-20,700.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.50",
          "val2": "-21.70",
          "chgp": "-105.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-29,639.20%",
          "val2": "-304,029.40%",
          "chgp": "27,439.02%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.40

-2.70

11.11%

Interest

0.00

Exceptional Items

-0.50

-5.30

90.57%

Consolidate Net Profit

-3.10

-8.20

62.20%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 62.20% vs -41.38% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.60

0.10

500.00%

Operating Profit (PBDIT) excl Other Income

-15.60

-19.60

20.41%

Interest

6.80

0.60

1,033.33%

Exceptional Items

-20.80

-0.10

-20,700.00%

Consolidate Net Profit

-44.50

-21.70

-105.07%

Operating Profit Margin (Excl OI)

-29,639.20%

-304,029.40%

27,439.02%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 500.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -105.07% vs 11.79% in Dec 2023

All Annual Results

Company CV

About Eterna Therapeutics, Inc.

Eterna Therapeutics, Inc.

Pharmaceuticals & Biotechnology

NTN Buzztime, Inc., formerly Alroy Industries, delivers entertainment and dining technology to bars and restaurants in North America. The Company provides an entertainment and marketing services platform for hospitality venues that offers games, events, and entertainment experiences to their customers. Its customers offer guests trivia, card, sports and arcade games, nationwide competitions, and self-service dining features, including dynamic menus, touchscreen ordering and secure payment by licensing the Company's customizable solution. Its platform creates connections among the players and venues. Its network subscriber venues are related to national and regional restaurant brands, including Buffalo Wild Wings, Old Chicago, Beef O'Brady's, Aroogas, Buffalo Wings & Rings, Native New Yorker and Boston Pizza. Its entertainment system enables players to interact at the venue, and it also enables competition between venues, referred to as multiplayer gaming.

Company Coordinates

Company Details

6965 El Camino Real, Suite 105-Box 517 , CARLSBAD CA : 92009

Tel: 1 760 43874001 415 4333777

https://www.buzztime.com/home

Registrar Details

Eterna Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

What does Eterna Therapeutics, Inc. do?

Watch in Real-Time

Who are in the management team of Eterna Therapeutics, Inc.?

Is Eterna Therapeutics, Inc. technically bullish or bearish?

Is Eterna Therapeutics, Inc. overvalued or undervalued?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Eterna Therapeutics Hits 52-Week Low Amid Significant Market Decline

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Eterna Therapeutics, Inc.

Company Coordinates